We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+37.43%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$239M
Cap. Flow
+$108M
Cap. Flow %
8.34%
Top 10 Hldgs %
67.1%
Holding
47
New
6
Increased
10
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$35.2M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$24.6M
3
ALLK
Allakos
ALLK
+$20.1M
4
VRNA
Verona Pharma
VRNA
+$17.7M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.9M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$47.9M
2
VRDN icon
Viridian Therapeutics
VRDN
+$11.3M
3
PCVX icon
Vaxcyte
PCVX
+$6.08M
4
KRYS icon
Krystal Biotech
KRYS
+$5.56M
5
PASG icon
Passage Bio
PASG
+$2.47M

Sector Composition

Rank Sector Weight
1 Healthcare 98.83%
2 Miscellaneous 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYRA icon
26
Tyra Biosciences
TYRA
$1.49B
$11.7M 0.9%
1,327,665
-47,400
-3% -$434K
NTLA icon
27
Intellia Therapeutics
NTLA
$1.8B
$11.4M 0.88%
203,684
– –
CERE
28
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$11.1M 0.86%
393,000
+190,740
+94% +$5.68M
STRO icon
29
Sutro Biopharma
STRO
$339M
$9.86M 0.76%
177,648
– –
GRCL
30
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$9.31M 0.72%
2,890,102
-221,449
-7% -$720K
BLUE
31
DELISTED
bluebird bio
BLUE
$9.12M 0.7%
+72,038
New +$8.15M
SLN
32
Silence Therapeutics
SLN
$834M
$8.7M 0.67%
881,173
– –
TRVI icon
33
Trevi Therapeutics
TRVI
$2.39B
$8.32M 0.64%
5,403,590
+4,231,963
+361% +$13.9M
AUTL
34
Autolus Therapeutics
AUTL
$623M
$8.02M 0.62%
3,746,857
– –
ACRS icon
35
Aclaris Therapeutics
ACRS
$885M
$6.43M 0.49%
408,329
– –
PASG icon
36
Passage Bio
PASG
$14.5M
$4.7M 0.36%
187,846
-62,615
-25% -$2.47M
IMVT icon
37
Immunovant
IMVT
$8.51B
$3.27M 0.25%
585,759
– –
MGNX icon
38
MacroGenics
MGNX
$263M
$2.43M 0.19%
+701,631
New +$2.68M
PRDS
39
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.56M 0.12%
845,636
– –
EPIX
40
DELISTED
ESSA Pharma
EPIX
$1.26M 0.1%
692,910
– –
MTEM
41
DELISTED
Molecular Templates, Inc.
MTEM
$1.03M 0.08%
91,603
– –
APTX
42
DELISTED
Aptinyx Inc. Common Stock
APTX
$693K 0.05%
1,883,244
– –
NBRV
43
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$35K ﹤0.01%
17,025
-1
-0% -$4
VRDN icon
44
Viridian Therapeutics
VRDN
$2.61B
– –
-980,302
Closed -$11.3M
ISEE
45
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-170,000
Closed -$1.64M
EPZM
46
DELISTED
Epizyme, Inc
EPZM
– –
-739,369
Closed -$1.09M
SRRA
47
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-870,636
Closed -$47.9M
1
2

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q3 2022 Portfolio in Review

As of Q3 2022, Frazier Life Sciences Management held 47 positions worth $1.3B, up 23% from $1.06B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Frazier Life Sciences Management deployed $108M of net new capital in Q3 2022, opening 6 new positions and adding to 10 existing holdings. Its largest new stake was Rhythm Pharmaceuticals: 1,894,000 shares worth $46.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Vaxcyte, an estimated $6.08M trimmed.

  • Frazier Life Sciences Management's largest Q3 2022 buy was Rhythm Pharmaceuticals: 1,894,000 shares worth $46.4M.
  • Frazier Life Sciences Management added most to Phathom Pharmaceuticals in Q3 2022, an estimated $24.6M increase.
  • Frazier Life Sciences Management's biggest Q3 2022 reduction was Vaxcyte, cutting an estimated $6.08M.
  • Frazier Life Sciences Management fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $47.9M.
  • Frazier Life Sciences Management's ten largest holdings make up 67% of its $1.3B portfolio in Q3 2022.
  • Frazier Life Sciences Management opened 6 new positions and closed 4 in Q3 2022.
  • Frazier Life Sciences Management's portfolio value rose 23% quarter-over-quarter to $1.3B.

Based on Frazier Life Sciences Management's 13F filing for Q3 2022, filed 14 Nov 2022.